Could a Dolutegravir-Based Antiretroviral Therapy Lead to Clinical Obesity? A Retrospective Cohort Study Conducted at Hawassa University Comprehensive Specialized Hospital in Hawassa, Sidama, Ethiopia.
By Aberash EifaWorku Ketema BededaPublished in: AIDS research and treatment (2022)
According to this study, tenofovir/lamivudine/dolutegravir (TLD)-based antiretroviral medication (ART) users are more likely to gain weight, and clinicians should advise them of the risks of weight gain as well as cost-effective ways to prevent weight gain linked to poor health outcomes in these patients. Future investigations should confirm the findings of this study, and more research into the effects of weight gain in these people is required.
Keyphrases
- weight gain
- antiretroviral therapy
- body mass index
- hiv infected patients
- birth weight
- hiv infected
- human immunodeficiency virus
- weight loss
- hiv positive
- hiv aids
- healthcare
- palliative care
- newly diagnosed
- type diabetes
- physical activity
- adipose tissue
- skeletal muscle
- risk assessment
- insulin resistance
- human health
- patient reported outcomes